FDA Downgrades Bone Stimulators to Easier Approval Class
Published Date: 4/16/2026
Rule
Summary
The FDA is changing the rules for non-invasive bone growth stimulators, moving them from the strictest category (Class III) to a less strict one (Class II) with special safety checks. This means companies will have an easier, faster path to get these devices approved, starting May 18, 2026. Patients and makers of these devices can expect safer products without big delays or extra costs.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Manufacturers get 510(k) pathway
If you make non-invasive bone growth stimulators (product codes LOF and LPQ), the FDA is reclassifying them from Class III to Class II effective May 18, 2026. That means you may submit a premarket notification (a 510(k)) instead of a premarket approval (PMA), which the FDA says reduces regulatory burden and typically shortens review timelines.
Patients may get faster access
If you need a non-invasive bone growth stimulator, reclassification to Class II (effective May 18, 2026) means the FDA expects more manufacturers to develop these devices and patients to get more timely access. The FDA says faster 510(k) reviews should help patients receive these devices sooner.
New testing, imaging, and labeling rules
Manufacturers must provide clinical and non-clinical performance data to support 510(k)s. The final order requires imaging data that demonstrates fusion at the treatment site, validation and verification of thermal safety and thermal reliability, characterization that signal outputs are within safe physiologic limits, device reliability over expected use-life, and electromagnetic compatibility (EMC) testing (FDA suggests standards such as IEC 60601-1-2). Labeling must include warnings for patients with implanted electrically powered devices and, where applicable, specify separation distances.
No extra postmarket surveillance required
FDA decided not to require additional postmarket surveillance beyond standard medical device reporting (MDR) requirements for non-invasive bone growth stimulators. FDA says the long history of use and the clinical data special control provide reasonable assurance of safety and effectiveness.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07365 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Transcutaneous Electrical Nerve Stimulator for the Relief of Congestion
The FDA is officially classifying the transcutaneous electrical nerve stimulator for relieving congestion as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the device safer and easier to get for patients, starting April 16, 2026, with the classification retroactive to March 5, 2021. Manufacturers will benefit from clearer rules and potentially lower costs while patients get quicker access to this cool congestion relief tech.
Next: 2026-07367 — Medical Devices; Orthopedic Devices; Classification of the Manual Surgical Instrument for Appropriate Patient Selection for Orthopedic Implant
The FDA is officially putting the manual surgical tool used to pick the right patients for orthopedic implants into a safer, more controlled category called Class II. This change helps make sure the tool works well and is safe, while also making it easier for new, helpful devices to reach patients faster. The new rules took effect on April 16, 2026, and could save time and money by cutting unnecessary red tape.